Author:
De Carlis Riccardo,Lauterio Andrea,Ficarelli Alberto,Vella Ivan,De Carlis Luciano
Publisher
Springer International Publishing
Reference36 articles.
1. Erridge S, Pucher PH, Markar SR, et al. Meta-analysis of determinants of survival following treatment of recurrent hepatocellular carcinoma. Br J Surg. 2017;104(11):1433–42.
2. Yang JD, Hainaut P, Gores GJ, et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16(10):589–604.
3. Raccomandazioni multisocietarie italiane (AISF, AIOM, IT-IHPBA, SIC, SIRM, SITO) per la gestione integrata del paziente con epatocarcinoma [Italian multisocietary recommendations (AISF, AIOM, IT-IHPBA, SIC, SIRM, SITE) for the integrated clinical management of the patient with hepatocellular carcinoma]. 2016. https://www.chirurgiadelfegato.it/wp-content/uploads/2020/04/raccomandazioni-multisocietarie_HCC.pdf. Accessed 20 Dec 2021.
4. Omata M, Cheng AL, Kokudo N, et al. Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017;11(4):317–70.
5. Korean Liver Cancer Association; National Cancer Center. 2018 Korean Liver Cancer Association-National Cancer Center Korea practice guidelines for the management of hepatocellular carcinoma. Gut Liver. 2019;13(3):227–99.